Navigation Links
Plavix may be treatment for dogs at risk of thromboembolic disease
Date:7/14/2010

Athens, Ga. Companion animals that have a long-term need for anticoagulant drug therapies may soon find help in a top-selling antiplatelet drug marketed to humans: clopidogrel, commonly known by the trade-name Plavix.

Researchers in the University of Georgia College of Veterinary Medicine have found that clopidogrel may be a safe and effective treatment for dogs that need long-term anticoagulant therapy. In addition, it may offer a safe alternative to NSAIDs for treating dogs at risk of thromboembolism due to concurrent therapeutic use of corticosteroids.

Other than aspirin, there are currently no approved antiplatelet drug therapies available to prophylactically treat companion animals with known or suspected hypercoagulability. Anticoagulants such as heparin, which must be administered by injection, are often used instead, but for patients who need long-term treatment, the researchers on the study said many animal owners are reluctant to administer injectable drugs to their pets.

In addition, critically ill dogs are at risk for thromboembolic disease, including pulmonary and aortic thromboembolism, both of which are associated with severe illness and death. Dogs that develop thrombosis and are subsequently treated with thrombolytic agents are at a substantial risk of hemorrhage or metabolic instability.

The researchers wanted to evaluate clopidogrel as a potential treatment for dogs with hypercoagulability due to excessive platelet activation. Clopidogrel, which is only available as an oral therapy, has been safely administered to cats, rabbits and calves, but little has been published about its effects in dogs.

In a study of healthy dogs, researchers found that most dogs had a significant inhibition of platelet function within three hours of receiving clopidogrel. All of the dogs in the study tolerated the drug well and showed no evidence of bruising, hemorrhage or other adverse effects. In addition, platelet activity returned to normal levels within approximately seven days after the drug was discontinued, which is similar to the response found in humans.

The researchers caution that their study only provides data on the effectiveness of clopidogrel in healthy dogs, and not on dogs that are critically ill or receiving other drugs. Further pharmacokinetic and pharmacodynamic studies in critically ill canine patients are planned, in addition to studies evaluating this drug in healthy horses.


'/>"/>

Contact: Kat Gilmore
kygilmore@uga.edu
706-583-5485
University of Georgia
Source:Eurekalert

Related biology news :

1. Breast cancer treatment resistance linked to signaling pathway
2. The dietary supplement genistein can undermine breast cancer treatment
3. Coming soon: Self-guided, computer-based depression treatment
4. Nanodiamond drug device could transform cancer treatment
5. Disinfectants can make bacteria resistant to treatment
6. Scientists from Granada find a potential treatment to prevent diabetes and obesity
7. FSU researchers discovery leads to $1.5 million grant, potential new treatment of liver fibrosis
8. Researchers at National Jewish Health evaluating a treatment
9. National Jewish Health researchers evaluating treatment to help emphysema sufferers breathe easier
10. First comprehensive genomic study of common cold reveals new treatment targets
11. Iowa State researcher develops new treatment method for canine eye diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2017)... Calif. , April 13, 2017 UBM,s ... York will feature emerging and evolving technology ... Both Innovation Summits will run alongside the expo portion ... speaker sessions, panels and demonstrations focused on trending topics ... largest advanced design and manufacturing event will take place ...
(Date:4/11/2017)... MELBOURNE, Florida , April 11, 2017 ... "Company"), a security technology company, announces the appointment of independent ... John Bendheim to its Board of Directors, furthering the ... ... behalf of NXT-ID, we look forward to their guidance and ...
(Date:4/4/2017)... 2017   EyeLock LLC , a leader of ... States Patent and Trademark Office (USPTO) has issued U.S. ... of an iris image with a face image acquired ... company,s 45 th issued patent. ... given the multi-modal biometric capabilities that have recently come ...
Breaking Biology News(10 mins):
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and ... rebranding initiative announced today. The bold new look is part of a transformation ... moves into a significant growth period. , It will also expand its service offering ...
(Date:10/10/2017)... -- International research firm Parks Associates announced today that ... TMA 2017 Annual Meeting , October 11 in Scottsdale, Arizona ... market and how smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase ... "The residential security market has experienced continued growth, ...
(Date:10/9/2017)... Oct. 9, 2017  BioTech Holdings announced today ... which its ProCell stem cell therapy prevents limb ... The Company, demonstrated that treatment with ProCell resulted ... saved as compared to standard bone marrow stem ... resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... Texas (PRWEB) , ... October ... ... study published on October 5, 2017, in the medical journal, Epilepsia, Brain ... with the gold standard, video EEG, in detecting generalized tonic-clonic seizures (GTCS) ...
Breaking Biology Technology: